259 related articles for article (PubMed ID: 31938815)
21. Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO).
Alvaro D; Cannizzaro R; Labianca R; Valvo F; Farinati F; ; ; ;
Dig Liver Dis; 2010 Dec; 42(12):831-8. PubMed ID: 20702152
[TBL] [Abstract][Full Text] [Related]
22. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
23. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract][Full Text] [Related]
24. Advances in targeted therapy of cholangiocarcinoma.
Li Y; Yu J; Zhang Y; Peng C; Song Y; Liu S
Ann Med; 2024 Dec; 56(1):2310196. PubMed ID: 38359439
[TBL] [Abstract][Full Text] [Related]
25. The diagnosis and treatment of cholangiocarcinoma.
Vogel A; Wege H; Caca K; Nashan B; Neumann U
Dtsch Arztebl Int; 2014 Oct; 111(44):748-54. PubMed ID: 25412632
[TBL] [Abstract][Full Text] [Related]
26. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract][Full Text] [Related]
27. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
[TBL] [Abstract][Full Text] [Related]
28. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
29. Cholangiocarcinoma Therapeutics: An Update.
Nguyen MLT; Toan NL; Bozko M; Bui KC; Bozko P
Curr Cancer Drug Targets; 2021; 21(6):457-475. PubMed ID: 33563168
[TBL] [Abstract][Full Text] [Related]
30. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
32. [Not Available].
Mas L; Perrier A; Coulet F; Bachet JB
Bull Cancer; 2022 Nov; 109(11S):11S28-11S34. PubMed ID: 36535760
[TBL] [Abstract][Full Text] [Related]
33. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
34. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
Ruff SM; Roychowdhury S; Pawlik TM
Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
[TBL] [Abstract][Full Text] [Related]
35. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.
Walter D; Hartmann S; Waidmann O
Z Gastroenterol; 2017 Jun; 55(6):575-581. PubMed ID: 28376540
[TBL] [Abstract][Full Text] [Related]
36. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine.
Casadio M; Biancaniello F; Overi D; Venere R; Carpino G; Gaudio E; Alvaro D; Cardinale V
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070643
[TBL] [Abstract][Full Text] [Related]
37. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
38. Current State of Multidisciplinary Treatment in Cholangiocarcinoma.
Ben Khaled N; Jacob S; Rössler D; Bösch F; De Toni EN; Werner J; Ricke J; Mayerle J; Seidensticker M; Schulz C; Fabritius MP
Dig Dis; 2022; 40(5):581-595. PubMed ID: 34695826
[TBL] [Abstract][Full Text] [Related]
39. Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study.
Wong M; Kim J; George B; Eriksen C; Pearson T; Robbins J; Zimmerman MA; Hong JC
J Surg Res; 2019 Oct; 242():23-30. PubMed ID: 31059945
[TBL] [Abstract][Full Text] [Related]
40. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
